Correction to: Neuropsychopharmacology https://doi.org/10.1038/s41386-023-01635-y, published online 30 June 2023
The original online version of this article was revised: In the sentence “Whereas some treatments are already available through off-label prescriptions (i.e R-ketamine [2]), most novel and rapid treatments are legally or practicably restricted to the realm of clinical studies (e.g., LSD, psilocybin, ayahuasca, closed-loop neuromodulation) [3, 4]”, ‘R-ketamine’ was corrected to ‘ketamine’. The original article has been corrected.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.
About this article
Cite this article
Haeusermann, T., Chiong, W. Correction: Ethical considerations in rapid and novel treatments in psychiatry. Neuropsychopharmacol. 49, 296 (2024). https://doi.org/10.1038/s41386-023-01669-2
Published:
Issue Date:
DOI: https://doi.org/10.1038/s41386-023-01669-2
